Zenith Capital (Zenith Capital) Net Margin % : 0.00% (As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Zenith Capital's Net Income for the three months ended in . 20 was $0.00 Mil. Zenith Capital's Revenue for the three months ended in . 20 was $0.00 Mil. Therefore, Zenith Capital's net margin for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for Zenith Capital's Net Margin % or its related term are showing as below:

ZHCLF's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -151.78
* Ranked among companies with meaningful Net Margin % only.

Zenith Capital Net Margin % Historical Data

The historical data trend for Zenith Capital's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Net Margin % Chart

Zenith Capital Annual Data

Trend

Net Margin %

Zenith Capital Quarterly Data

Net Margin %

Competitive Comparison of Zenith Capital's Net Margin %

For the Biotechnology subindustry, Zenith Capital's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Net Margin % distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Net Margin % falls into.

Zenith Capital Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Zenith Capital's Net Margin for the fiscal year that ended in . 20 is calculated as

Net Margin	=	Net Income (A: . 20 )	/	Revenue (A: . 20 )
	=		/
	=	%

Zenith Capital's Net Margin for the quarter that ended in . 20 is calculated as

Net Margin	=	Net Income (Q: . 20 )	/	Revenue (Q: . 20 )
	=		/
	=	%

Zenith Capital (OTCPK:ZHCLF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Zenith Capital Net Margin % Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines